Surgical & Medical Instruments & Apparatus
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. It manufactures and sells implants and instruments through third-party suppliers. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform; Sigma PTP Access and Patient Positioning System; split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; EOS imaging system that provides full-body imaging; spinal implants and fixation systems; and NanoTec and Calibrate PSX, as well as various standalone implants for height restoration and stabilization. It also provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix, a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM; AlphaGRAFT Demineralized Bone Matrix comprising demineralized human tissues; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives in the United States and internationally. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Sector
In the chart Earnings are multiplied by this value.
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Net Margin | -96% | -25% | -2.3% | -46% | -50% | -55% | -59% | -43% | -39% | -37% |
ROA | -110% | -16% | -5.4% | -17% | -28% | -23% | -22% | -29% | -22% | -23% |
ROE | 490% | 72% | 8.6% | -240% | -130% | -61% | -180% | 410% | -240% | -510% |
The average Net Margin over the past 5 years is -48.75%.
The trend of Net Margin over the past 5 years is +1.54%.
The average ROA over the past 5 years is -23.37%.
The trend of ROA over the past 5 years is -0.67%.
The average ROE over the past 5 years is -73.22%.
The trend of ROE over the past 5 years is +43.65%.
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Debt FCF | -77.58 | -2.78 | -2.83 | -1.64 | -1.34 | -0.85 | -2.37 | -3.10 | -3.32 | -2.73 |
Debt Equity | -4.50 | -1.26 | -1.73 | 2.99 | 1.41 | 0.46 | 4.24 | -10.53 | 6.76 | 14.11 |
MIN | ||||||||||
Graham Stability | - | - | - | - | - | - | - | - | - | - |
The Debt/FCF trailing twelve month is -2.73.
The trend of Debt/FCF over the past 5 years is -0.44.
Graham’s Stability measure stands at -.
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
---|---|---|---|---|---|
Revenue | 22% | 39% | 49% | 37% | 11% |
Net Income | - | - | - | - | - |
Stockholders Equity | - | 35% | -16% | - | -94% |
FCF | - | - | - | - | - |
The Revenue CAGR over the past 5 years is +39.38%.
The trend of Revenue growth rate over the past 5 years is +10.57%.
The Earnings CAGR over the past 5 years is +34.46%.
The trend of Earnings growth rate over the past 5 years is -.
The Equity CAGR over the past 5 years is +34.76%.
The trend of Equity growth rate over the past 5 years is -93.56%.
The FCF CAGR over the past 5 years is +37.69%.
The trend of FCF growth rate over the past 5 years is -.